Zacks Investment Research upgraded shares of Natus Medical (NASDAQ:BABY) from a strong sell rating to a hold rating in a report issued on Tuesday, April 10th.
According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “
A number of other equities research analysts have also recently commented on the stock. William Blair cut shares of Natus Medical from an outperform rating to a market perform rating in a report on Monday, January 8th. BidaskClub cut shares of Natus Medical from a sell rating to a strong sell rating in a report on Saturday, January 6th. Roth Capital set a $39.00 price target on shares of Natus Medical and gave the stock a buy rating in a report on Tuesday, February 27th. Finally, Benchmark restated a buy rating and set a $49.00 target price (down from $55.00) on shares of Natus Medical in a research report on Tuesday, January 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $44.33.
Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.54 by ($0.12). Natus Medical had a positive return on equity of 11.36% and a negative net margin of 4.05%. The firm had revenue of $131.40 million for the quarter, compared to analyst estimates of $131.38 million. During the same quarter in the previous year, the firm posted $0.51 EPS. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. sell-side analysts anticipate that Natus Medical will post 1.63 earnings per share for the current fiscal year.
Natus Medical announced that its board has approved a stock repurchase plan on Thursday, February 22nd that allows the company to repurchase $30.00 million in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.
In other news, Director Ken Ludlum sold 4,000 shares of the stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $31.68, for a total value of $126,720.00. Following the sale, the director now directly owns 93,825 shares in the company, valued at $2,972,376. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in Natus Medical during the third quarter worth approximately $138,000. Elkfork Partners LLC acquired a new stake in Natus Medical during the fourth quarter worth approximately $163,000. Greenwood Capital Associates LLC acquired a new stake in Natus Medical during the fourth quarter worth approximately $219,000. First Capital Advisors Group LLC. acquired a new stake in Natus Medical during the fourth quarter worth approximately $222,000. Finally, Bessemer Group Inc. acquired a new stake in Natus Medical during the fourth quarter worth approximately $255,000. Hedge funds and other institutional investors own 95.83% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.